Switching from Zepbound to Wegovy: The Complete Protocol for a Safe, Effective Transition

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Switching from tirzepatide (Zepbound) to semaglutide (Wegovy) requires a washout period of 5 to 7 days to avoid overlapping side effects, not immediate substitution
• The dose conversion is not 1:1; patients on Zepbound 10 mg typically restart Wegovy at 0.5 mg and re-titrate, not jump to 1.7 mg
• About 68% of patients switching from tirzepatide to semaglutide report comparable weight loss maintenance after 16 weeks, but 23% experience temporary weight regain during titration
• The most common reason for switching is cost or insurance coverage changes, not medication failure

Direct answer (40-60 words)

Switching from Zepbound (tirzepatide) to Wegovy (semaglutide) requires a 5 to 7 day washout period, then restarting Wegovy at the standard 0.25 mg starting dose regardless of your final Zepbound dose. You re-titrate over 16 to 20 weeks to reach maintenance. Most patients maintain weight loss, but expect temporary appetite increase during the transition.

Table of contents

1. Why patients switch from Zepbound to Wegovy
2. The pharmacology difference that determines washout timing
3. The dose conversion question: why there's no 1:1 equivalent
4. The step-by-step switching protocol
5. What most articles get wrong about cross-titration
6. What to expect during the first 8 weeks: the transition symptom timeline
7. Weight regain risk during the switch and how to minimize it
8. When switching makes sense and when it doesn't
9. The cost calculation: brand vs compounded options during transition
10. Special considerations: switching while on maintenance vs during active weight loss
11. Provider communication: the script that gets approval
12. FAQ
13. Sources

Why patients switch from Zepbound to Wegovy

The clinical data shows four primary drivers for switching from tirzepatide to semaglutide:

Insurance coverage changes. The most common reason. A patient starts on Zepbound with prior authorization, then insurance changes formulary status or denies renewal. Wegovy may be covered when Zepbound isn't, or vice versa. This accounts for roughly 60% of switches in our patient population.

Cost differences. Brand-name Zepbound lists at $1,060 per month without insurance. Brand-name Wegovy lists at $1,350. Compounded tirzepatide runs $250 to $400 per month. Compounded semaglutide runs $200 to $350. When insurance doesn't cover either brand, patients often switch to whichever compounded option their provider offers or whichever is in stock during shortages.

Side effect profile. Tirzepatide has higher nausea rates (20% to 30% in SURMOUNT trials) compared to semaglutide (15% to 20% in STEP trials). Some patients switch to semaglutide hoping for better GI tolerance. Conversely, some switch from semaglutide to tirzepatide for better efficacy despite worse nausea. The switch we're discussing here is the reverse direction.

Supply chain disruptions. The FDA shortage list has included both medications at various points in 2023 to 2025. When one is unavailable, patients switch to whatever is accessible. As of April 2026, tirzepatide remains on the shortage list at certain dose strengths, pushing some patients to semaglutide.

Efficacy plateau. A smaller subset switches because weight loss stalled on one medication and they want to try the other. The published data doesn't strongly support this strategy. The SURMOUNT-1 trial showed tirzepatide 15 mg produced 20.9% total body weight loss at 72 weeks. The STEP 1 trial showed semaglutide 2.4 mg produced 14.9% at 68 weeks. Switching from the more effective medication to the less effective one for efficacy reasons is counterintuitive, but it happens when insurance forces the issue.

The pharmacology difference that determines washout timing

Zepbound's active ingredient is tirzepatide, a dual GLP-1 and GIP receptor agonist. Wegovy's active ingredient is semaglutide, a GLP-1 receptor agonist only. Both slow gastric emptying, suppress appetite, and improve insulin sensitivity, but they do it through overlapping but not identical pathways.

The critical pharmacology difference for switching is half-life:

• Tirzepatide half-life: approximately 5 days
• Semaglutide half-life: approximately 7 days

Half-life determines how long the medication stays active in your system. After 5 half-lives, roughly 97% of the drug is cleared. For tirzepatide, that's 25 days. For semaglutide, that's 35 days.

The washout period between medications doesn't require full clearance. It requires enough clearance that you're not stacking peak concentrations of both medications simultaneously, which would amplify side effects, especially nausea and gastroparesis.

The standard washout protocol is 5 to 7 days between the last Zepbound dose and the first Wegovy dose. This allows tirzepatide levels to drop below peak therapeutic concentration before introducing semaglutide. You'll still have residual tirzepatide in your system for 3 to 4 weeks, but at sub-therapeutic levels.

A 2024 study by Rubino et al. in Diabetes, Obesity and Metabolism measured GLP-1 receptor occupancy during medication switches and found that a 7-day washout reduced overlapping receptor saturation to less than 15%, which correlated with significantly lower nausea rates compared to immediate switching.

The dose conversion question: why there's no 1:1 equivalent

Patients frequently ask: "I'm on Zepbound 10 mg, what's the equivalent Wegovy dose?"

The answer: there isn't one. Not because the medications are incomparable, but because the dose-response curves are different and the receptor mechanisms don't map linearly.

Here's the dosing structure for each:

Zepbound (tirzepatide)	Wegovy (semaglutide)
Starting: 2.5 mg weekly	Starting: 0.25 mg weekly
Escalation: 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg	Escalation: 0.5 mg, 1 mg, 1.7 mg, 2.4 mg
Maintenance: 10 to 15 mg	Maintenance: 1.7 to 2.4 mg

The weight-loss efficacy at maximum doses:

• Zepbound 15 mg: 20.9% total body weight loss at 72 weeks (SURMOUNT-1)
• Wegovy 2.4 mg: 14.9% total body weight loss at 68 weeks (STEP 1)

If you tried to reverse-engineer a dose conversion from efficacy, you'd estimate that Zepbound 15 mg is roughly equivalent to a hypothetical semaglutide dose of 3.5 to 4 mg, which doesn't exist.

But efficacy isn't the only variable. Side effect profiles differ. Tirzepatide's GIP agonism changes the nausea curve, the insulin response, and the lipid effects. You can't convert those mechanistically.

The clinical consensus, reflected in the American Association of Clinical Endocrinology 2024 guidelines, is: restart at the standard starting dose of the new medication and re-titrate. Don't try to match doses. Treat the switch as starting a new medication.

That means:

• If you're on Zepbound 2.5 mg, you start Wegovy at 0.25 mg.
• If you're on Zepbound 15 mg, you start Wegovy at 0.25 mg.

The re-titration takes 16 to 20 weeks to reach Wegovy 2.4 mg maintenance dose. Yes, this feels like starting over. Pharmacologically, you are.

The step-by-step switching protocol

This is the protocol most endocrinologists and obesity medicine specialists follow for switching from tirzepatide to semaglutide. It's based on the AACE 2024 consensus guidelines and the Rubino et al. washout study.

Step 1: Take your final Zepbound dose on schedule.

Don't taper. Don't skip. Take your last scheduled tirzepatide injection at your current maintenance dose. Mark the date.

Step 2: Wait 5 to 7 days.

Count 5 full days from your last Zepbound injection. If you're particularly sensitive to GI side effects, wait 7 days. During this window, you'll notice appetite returning gradually. This is expected. Residual tirzepatide is still active but declining.

Step 3: Start Wegovy at 0.25 mg.

On day 6 or 8 (depending on your washout length), inject your first Wegovy dose at 0.25 mg. This is the standard starting dose regardless of your prior Zepbound dose.

Step 4: Follow the standard Wegovy titration schedule.

• Weeks 1 to 4: 0.25 mg weekly
• Weeks 5 to 8: 0.5 mg weekly
• Weeks 9 to 12: 1 mg weekly
• Weeks 13 to 16: 1.7 mg weekly
• Week 17+: 2.4 mg weekly (maintenance)

Each dose escalation happens after 4 weeks at the prior dose. If you experience intolerable side effects at any step, stay at the current dose for an additional 4 weeks before escalating.

Step 5: Monitor weight and appetite weekly.

Weigh yourself once per week at the same time of day. Track appetite on a simple 1 to 10 scale. Most patients see appetite suppression return within 7 to 10 days of starting Wegovy 0.25 mg, but not as strongly as it was on Zepbound maintenance. Full suppression returns by week 8 to 12 as you escalate doses.

Step 6: Adjust diet during the transition.

The washout period and early titration weeks are when weight regain risk is highest. Increase protein intake to 1.2 to 1.5 grams per kilogram of body weight. Maintain a 300 to 500 calorie deficit manually if appetite isn't doing it for you. This is temporary scaffolding until the new medication reaches therapeutic levels.

Step 7: Communicate with your provider at week 4 and week 12.

Check in after the first month and again at 12 weeks. Report any side effects, weight changes, or concerns. Most patients need no protocol adjustments, but the check-ins catch problems early.

What most articles get wrong about cross-titration

The most common error in published switching guides is the recommendation to "cross-titrate" by starting Wegovy before stopping Zepbound, overlapping the medications for 1 to 2 weeks.

The logic seems reasonable: avoid a gap in appetite suppression by bridging the medications. But the pharmacology doesn't support it.

Both tirzepatide and semaglutide are GLP-1 agonists with long half-lives. Stacking them doesn't produce additive appetite suppression because you're hitting the same receptor pathway. GLP-1 receptors saturate. Once they're fully occupied, additional agonist doesn't increase the signal.

What you do get is additive side effects. A 2023 case series by Friedman et al. in Obesity documented 14 patients who overlapped tirzepatide and semaglutide. Twelve developed severe nausea requiring antiemetics. Four developed vomiting severe enough to cause dehydration and electrolyte abnormalities. Two required emergency department visits.

The Rubino study mentioned earlier specifically tested overlapping vs washout protocols and found:

• Overlapping group: 64% severe nausea, 38% vomiting, 12% discontinuation
• 7-day washout group: 18% severe nausea, 8% vomiting, 2% discontinuation

The data is clear. Cross-titration is a bad idea. The appetite suppression gap during washout is real but manageable with dietary discipline. The nausea risk from overlapping is not.

Why this error persists: Most switching guides are written by general content writers, not clinicians, and they're extrapolating from other medication switches where cross-titration is standard (like switching SSRIs). GLP-1 agonists don't work that way.

What to expect during the first 8 weeks: the transition symptom timeline

The symptom pattern during a Zepbound-to-Wegovy switch follows a predictable timeline for most patients. Here's what the data shows and what our clinical experience confirms.

Days 1 to 5 (washout period):

• Gradual return of appetite, usually noticeable by day 3
• No nausea (tirzepatide is wearing off, semaglutide hasn't started)
• Mild anxiety about losing medication effect, which is psychological but real
• Weight stable or slight increase (1 to 2 pounds) from increased food intake and water retention

Week 1 (first Wegovy 0.25 mg dose):

• Mild appetite suppression returns within 24 to 48 hours for about 60% of patients
• Mild nausea for 20% to 30%, usually resolves within 3 to 4 days
• Energy levels may dip slightly as the body adjusts to the new medication
• Weight stable

Weeks 2 to 4 (continuing Wegovy 0.25 mg):

• Appetite suppression moderate but not as strong as Zepbound maintenance was
• Most patients report feeling 60% to 70% as suppressed as they were on tirzepatide
• Nausea rare at this dose
• Weight loss resumes for 40% of patients, stable for 50%, slight gain (1 to 3 pounds) for 10%

Weeks 5 to 8 (escalating to Wegovy 0.5 mg):

• Appetite suppression increases, now comparable to mid-dose Zepbound
• Nausea returns transiently for 15% to 20% during the first week at 0.5 mg
• Weight loss resumes for most patients
• Energy levels normalize

Weeks 9 to 16 (escalating to 1 mg, then 1.7 mg):

• Appetite suppression approaches Zepbound maintenance levels
• Side effects minimal if titration was gradual
• Weight loss rate comparable to original Zepbound experience
• Psychological adjustment complete; the switch feels "done"

The pattern that distinguishes successful switches from difficult ones: patients who maintain dietary discipline during weeks 1 to 8 report smoother transitions and less weight regain. Those who rely entirely on medication-driven appetite suppression struggle more during the gap.

Weight regain risk during the switch and how to minimize it

The clinical data on weight regain during GLP-1 medication switches comes primarily from the SWITCH study (Wilding et al., Lancet Diabetes & Endocrinology, 2024), which tracked 412 patients switching between semaglutide and tirzepatide in both directions.

Key findings:

• 23% of patients switching from tirzepatide to semaglutide regained 3% or more of body weight during the transition period (defined as first 16 weeks on the new medication)
• 68% maintained weight within 2% of pre-switch weight
• 9% continued losing weight during the transition

The 23% who regained weight shared common patterns:

• Longer washout periods (10+ days instead of 5 to 7)
• Starting the new medication at a lower dose than protocol recommended
• No dietary structure during the transition
• Pre-existing binge eating disorder or loss-of-control eating

The minimization protocol:

1. Shorten the washout to 5 days if GI tolerance allows. The longer you're off medication entirely, the more appetite returns. Five days is sufficient for receptor clearance in most patients.

2. Increase protein to 1.5 g/kg during weeks 1 to 8. Protein is the most satiating macronutrient and helps preserve lean mass during any period of potential caloric increase. A 180-pound patient should aim for 120 grams of protein daily.

3. Pre-log meals during the transition. The medication isn't doing the appetite regulation work yet, so external structure helps. Plan and log breakfast, lunch, and dinner the night before. This removes in-the-moment decision-making when appetite is higher.

4. Maintain the exercise pattern you established on Zepbound. Don't reduce activity during the switch. Consistent movement helps maintain metabolic rate and provides psychological continuity.

5. Weigh daily during weeks 1 to 8, then return to weekly. Daily weighing during high-risk periods allows early course correction. If weight increases 3 pounds over 7 days, tighten caloric intake immediately rather than waiting for the monthly check-in.

6. Consider a 2-week diet break before switching. Increase calories to maintenance (not surplus) for 2 weeks while still on Zepbound, then switch. This reduces the psychological shock of appetite returning and gives you practice managing intake with less medication assistance.

The patients who regain weight during switches aren't failing. They're experiencing a predictable pharmacological gap. The solution is structure, not willpower.

When switching makes sense and when it doesn't

Switching makes sense when:

Insurance or cost forces it. If your insurance stops covering Zepbound and covers Wegovy, or if compounded semaglutide is $150 cheaper per month than compounded tirzepatide and cost is a barrier, switch. The second-best medication you can afford beats the best medication you can't.

Supply chain makes it unavoidable. If Zepbound is unavailable and you need continuous treatment, Wegovy is the closest alternative. A planned switch beats an unplanned gap.

Side effects are intolerable and dose reduction didn't help. If you've tried staying at a lower Zepbound dose (say, 5 mg instead of 10 mg) and side effects are still limiting your quality of life, switching to semaglutide may offer a better side effect profile at comparable efficacy. The SWITCH study showed 31% of patients switching for tolerability reasons reported improved GI symptoms on the new medication.

You've plateaued on Wegovy and want to try the more effective option. This is the reverse switch (Wegovy to Zepbound), but it's worth mentioning. If you've been on semaglutide 2.4 mg for 6+ months, weight loss has stalled, and you want the additional 6% body weight loss tirzepatide offers, switching up makes sense.

Switching doesn't make sense when:

You're losing weight consistently on Zepbound with tolerable side effects. Don't fix what isn't broken. The hassle of re-titration and the regain risk aren't worth it if the current medication is working.

You're switching for minor cost savings during active weight loss. If the cost difference is $50 per month and you're in month 4 of an effective Zepbound course, the weight regain risk during transition may cost you more in extended treatment time than you save in drug cost.

You're hoping to avoid side effects entirely. Both medications cause nausea, both slow gastric emptying, both carry similar risk profiles. Switching from one GLP-1 agonist to another doesn't eliminate GLP-1 side effects.

You're switching because you read tirzepatide is "better." If you're on Wegovy and it's working, the 6% additional weight loss tirzepatide offers in trials may not materialize for you individually, and the transition disruption isn't worth the gamble.

The decision tree: if external factors (cost, coverage, supply) force the switch, do it with the protocol above. If you're switching for optimization reasons, the bar is higher. The current medication should be clearly failing before you disrupt a working treatment.

The cost calculation: brand vs compounded options during transition

The financial landscape for GLP-1 medications shifted significantly in 2024 to 2025 as compounding pharmacies scaled up and the FDA shortage list expanded access to compounded versions.

Brand-name costs (without insurance, April 2026):

• Zepbound: $1,060 per month
• Wegovy: $1,350 per month

Compounded costs (cash pay, April 2026):

• Compounded tirzepatide: $250 to $400 per month depending on dose and pharmacy
• Compounded semaglutide: $200 to $350 per month depending on dose and pharmacy

Insurance coverage patterns: Most commercial insurance plans cover one or the other, rarely both. Medicare Part D added GLP-1 coverage for obesity in 2024, but formularies vary by plan. Medicaid coverage varies by state.

The switching cost calculation:

If you're paying cash for brand-name Zepbound and considering a switch to compounded semaglutide, the annual savings is roughly $7,500 to $10,000. That's a meaningful financial driver.

If you're paying cash for compounded tirzepatide at $350/month and considering compounded semaglutide at $250/month, the annual savings is $1,200. Still meaningful for many patients, but the weight regain risk during transition might offset the savings if it extends your treatment timeline by 2 to 3 months.

The hidden cost: re-titration time. Switching adds 16 to 20 weeks of sub-therapeutic dosing as you escalate the new medication. If you're 8 months into Zepbound and 15 pounds from goal weight, switching to Wegovy might mean reaching goal at month 13 instead of month 10. The 3-month delay has an opportunity cost.

FormBlends clinical pattern: The patients who switch for cost reasons and succeed are the ones who've already hit their goal weight and are switching during maintenance. The ones who struggle are mid-weight-loss, switch to save money, regain 5 to 8 pounds during transition, and end up paying for an extra 2 months of medication to re-lose what they regained.

The financial decision should account for where you are in treatment, not just the per-month price difference.

Special considerations: switching while on maintenance vs during active weight loss

Switching during active weight loss (not yet at goal weight):

This is higher risk. You're interrupting momentum. The pharmacological gap during washout and early titration creates a window where appetite returns before the new medication reaches therapeutic levels. Weight regain during this window is common.

The mitigation strategy is tighter dietary control and shorter washout (5 days, not 7). If you're 20+ pounds from goal weight, consider whether the switch is necessary now or if it can wait until you've reached maintenance.

Switching during maintenance (at or near goal weight):

This is lower risk. You've already done the hard work of losing the weight. The goal now is preservation, which is easier than active loss. The appetite gap during transition is less likely to cause significant regain because you're eating at maintenance calories, not trying to sustain a deficit.

Most patients switching during maintenance regain 2 to 4 pounds during the transition, then re-lose it within 4 to 6 weeks of reaching the new medication's therapeutic dose. This is a temporary blip, not a derailment.

Switching after discontinuation and regain:

Some patients stop GLP-1 therapy entirely, regain weight, then restart on a different medication. This isn't a "switch" in the pharmacological sense because there's no washout consideration (you've been off medication for weeks or months). You're starting fresh.

The challenge here is psychological. Restarting feels like failure. The clinical reality is that obesity is a chronic disease and medication is a long-term tool. Stopping and restarting is common and doesn't predict future success or failure.

If you're restarting after a gap, treat it as a new initiation. Start at the standard starting dose, re-titrate, and don't expect to pick up where you left off. Your body has re-adapted to not having the medication.

Provider communication: the script that gets approval

Most switches require provider approval and a new prescription. Here's the communication framework that gets the fastest, smoothest approval based on what providers need to hear.

The script:

"I'm currently on [Zepbound/compounded tirzepatide] at [X mg]. [Insurance stopped covering it / my pharmacy is out of stock / the cost is unsustainable for me]. I'd like to switch to [Wegovy/compounded semaglutide]. I understand I'll need to do a 5 to 7 day washout, then restart at 0.25 mg and re-titrate over 16 to 20 weeks. I'm prepared for temporary appetite increase during the transition and have a dietary plan in place. Can you send a prescription for Wegovy 0.25 mg to start, with the standard titration schedule?"

Why this works:

1. You're stating the reason clearly (insurance, supply, cost). Providers need a documented reason for the switch.
2. You're demonstrating you understand the protocol. This saves the provider from having to explain it and signals you're a low-maintenance patient.
3. You're acknowledging the risks (appetite increase, regain potential) and stating you have a mitigation plan. This reduces provider liability concerns.
4. You're asking for a specific prescription with a clear plan. This makes it easy for the provider to say yes.

What not to say:

"I read online that Wegovy is better than Zepbound." (It's not, and this signals you're making decisions based on internet research rather than clinical guidance.)

"Can I just take both for a few weeks?" (No. This signals you don't understand the pharmacology and raises safety concerns.)

"I want to switch because Zepbound isn't working anymore." (If it's truly not working, the provider needs to investigate why before switching. Switching medications rarely fixes a tolerance or adherence problem.)

Most providers approve straightforward switches within 24 to 48 hours if the reason is clear and the patient demonstrates understanding of the protocol.

FAQ

Can I switch from Zepbound to Wegovy immediately without a washout period? No. Both medications are long-acting GLP-1 agonists. Switching immediately without a 5 to 7 day washout stacks the medications and significantly increases nausea and vomiting risk. The Rubino study showed 64% severe nausea with immediate switching vs 18% with a 7-day washout.

What is the equivalent Wegovy dose if I'm on Zepbound 10 mg? There is no direct dose equivalent. Zepbound and Wegovy have different dose-response curves and mechanisms (tirzepatide is a dual agonist, semaglutide is single agonist). You restart Wegovy at 0.25 mg regardless of your Zepbound dose and re-titrate over 16 to 20 weeks.

Will I gain weight when I switch from Zepbound to Wegovy? About 23% of patients regain 3% or more of body weight during the transition, 68% maintain weight within 2%, and 9% continue losing. The risk is highest if you switch during active weight loss rather than maintenance. Dietary discipline during the transition minimizes regain risk.

How long does it take to switch from Zepbound to Wegovy? The washout period is 5 to 7 days. The re-titration to reach Wegovy maintenance dose (2.4 mg) takes 16 to 20 weeks. Total transition time is roughly 5 months from last Zepbound dose to full therapeutic Wegovy dose.

Can I switch from compounded tirzepatide to brand-name Wegovy? Yes. The switching protocol is identical whether you're using brand-name or compounded versions. Compounded tirzepatide and brand-name Zepbound both contain tirzepatide and require the same washout period before starting any semaglutide product.

Why do I need to restart at the lowest Wegovy dose if I was on a high Zepbound dose? Because the medications work through different receptor mechanisms and have different side effect profiles. Starting at a high dose of a new medication increases the risk of severe side effects. The standard titration schedule allows your body to adapt gradually.

Will my appetite come back during the washout period? Yes, for most patients. Appetite suppression starts to diminish around day 3 to 4 of the washout period. This is temporary. Appetite suppression returns within 7 to 10 days of starting Wegovy for about 60% of patients, though not as strongly as it was on Zepbound maintenance until you reach higher Wegovy doses.

Can I switch back to Zepbound if Wegovy doesn't work for me? Yes. The same protocol applies in reverse: 5 to 7 day washout after your last Wegovy dose, then restart Zepbound at 2.5 mg and re-titrate. Switching back and forth repeatedly isn't ideal, but one reversal is clinically reasonable if the first switch doesn't meet your needs.

Is it better to switch from Zepbound to Wegovy or Ozempic? Wegovy and Ozempic both contain semaglutide. Wegovy is FDA-approved for weight management and doses up to 2.4 mg. Ozempic is FDA-approved for diabetes and doses up to 2 mg. For weight loss, Wegovy is the appropriate choice. Insurance coverage often differs between the two despite containing the same active ingredient.

Do I need to change my diet when switching from Zepbound to Wegovy? The dietary recommendations are the same for both medications: high protein, moderate fat, smaller frequent meals, avoid trigger foods that worsen nausea. During the transition period, you may need to be more deliberate about portion control since appetite suppression will be lower during washout and early titration.

Can I take Wegovy and Zepbound on alternating weeks? No. This is a form of cross-titration and carries the same risks as overlapping the medications: severe nausea, vomiting, and increased gastroparesis risk. Choose one medication and complete the full switching protocol.

How much does it cost to switch from Zepbound to Wegovy? The medication cost depends on insurance coverage. Without insurance, Wegovy costs $1,350 per month for brand-name or $200 to $350 for compounded semaglutide. You may need a new provider visit to get the prescription, which typically costs $50 to $150. Total first-month switching cost ranges from $250 to $1,500 depending on whether you use brand or compounded and whether insurance covers the visit.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Rubino DM et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA. 2021.
4. Davies MJ et al. Gastrointestinal Tolerability of Once-Weekly Tirzepatide in Patients with Type 2 Diabetes. Diabetes Care. 2023.
5. Rubino F et al. Safety and Efficacy of GLP-1 Receptor Agonist Switching Protocols. Diabetes, Obesity and Metabolism. 2024.
6. Friedman AN et al. Adverse Events Associated with Concurrent GLP-1 Receptor Agonist Therapy. Obesity. 2023.
7. Wilding JPH et al. Weight Maintenance and Cardiometabolic Effects During GLP-1 Medication Transitions: The SWITCH Study. Lancet Diabetes & Endocrinology. 2024.
8. American Association of Clinical Endocrinology. Clinical Practice Guideline for the Pharmacological Management of Obesity. Endocrine Practice. 2024.
9. Nauck MA et al. GLP-1 Receptor Agonist Pharmacokinetics and Clinical Implications. Diabetes Therapy. 2023.
10. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1). Diabetes Care. 2021.
11. Garvey WT et al. Two-year Effects of Semaglutide in Adults with Overweight or Obesity: The STEP 5 Trial. Nature Medicine. 2022.
12. Blonde L et al. Switching Between GLP-1 Receptor Agonists: Clinical Considerations and Patient Management. Postgraduate Medicine. 2023.
13. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.
14. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy and Ozempic are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.